: We will improve QOL of CNS diseases’ patients and reduce burdens on family members by establishing a stem cell therapy method

Message from CEO



I’m a Neurologist with more than 10-year experience. I helped many patients but there were still many patients suffering from neurological disorders with no treatments.

I worked at Kyoto University to develop gene therapies for these patients until 2000. But I felt a limitation of gene therapies at that time.

Then, I decided to go to NIH to learn stem cell technologies. After 5 years, I established a bio-venture company, Stem Cell Medicine, LLC in US to develop a novel cell therapy product.

In 2011, I discovered a new type of human neural stem cells that can differentiate into oligodendrocytes efficiently and named it “OligoGenie”.

After its patent was granted in Japan and a new regulation was introduced in Novermber, 2014, I came back to Japan and establiced Oligogen, Inc. to initiate a clinical trial for Pelizaeus-Merzbacher disease, multiple sclerosis and spinal cord injury.

We have gotten Series-A investments from venture caplitals in August, 2017 and moved into Innovation Hub Kyoto in 2018.

Now, we are working hard to provide "OligoGenie" for patients with neurological disorders, such as Pelizaeus-Merzbacher disease (PMD), Multiple sclerosis, Spinal cord injuries, Alzheimer disease, etc.

Tsuneo Kido, President & CEO